Journal
NEUROPSYCHOPHARMACOLOGY
Volume 45, Issue 9, Pages 1411-1422Publisher
SPRINGERNATURE
DOI: 10.1038/s41386-020-0697-9
Keywords
-
Categories
Funding
- Department of Veterans Affairs [I01 CX001443]
- NIH [R01 MH093450]
- Janssen Fellowship in Translational Neuroscience
- OHSU Physician Scientist Award
- NIH NIBIB [R01EB028161]
- NIH NINDS [UF1-NS17666-01]
- [MH49334]
- [MH109289]
- [5KL2TR001854]
- [R01 MH075916-05]
- [U01 MH076989]
- [R01MH112180]
- [R01MH116948]
- [AA006059]
- [019969]
- [026248]
- [027316]
- [MH120117]
- [MH114223]
- [MH113041]
- [R01DC012947]
- [P50MH109429]
Ask authors/readers for more resources
New treatment development for psychiatric disorders depends critically upon the development of physiological measures that can accurately translate between preclinical animal models and clinical human studies. Such measures can be used both as stratification biomarkers to define pathophysiologically homogeneous patient populations and as target engagement biomarkers to verify similarity of effects across preclinical and clinical intervention. Traditional time-domain event-related potentials (ERP) have been used translationally to date but are limited by the significant differences in timing and distribution across rodent, monkey and human studies. By contrast, neuro-oscillatory responses, analyzed within the time-frequency domain, are relatively preserved across species permitting more precise translational comparisons. Moreover, neuro-oscillatory responses are increasingly being mapped to local circuit mechanisms and may be useful for investigating effects of both pharmacological and neuromodulatory interventions on excitatory/inhibitory balance. The present paper provides a roadmap for development of neuro-oscillatory responses as translational biomarkers in neuropsychiatric treatment development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available